The combination of the PentaMice® platform and single B cell screening with the Berkeley Lights Beacon® Optofluidic system increases speed to market for monoclonal antibody therapeutics.
The Beacon® system is an innovative package using the technology of light, nanofluidics and refined AI algorithms to identify and orchestrate the movement of single B cells into a grid of NanoPen™ chambers for screening.
Download our white paper for insights on:
- First-to-Human antibody therapeutics
- Immunization — PentaMice® platform for antibody generation
- Single B cell screening with the Beacon® system
- Sequence Identification
- Custom Bioinformatics
- Case Study: Discovery of diverse monoclonal antibodies that bind SARS-CoV-2 Delta and Omicron spike proteins
More from Curia
While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lin...